再生医学：潜力巨大，但尚未完全准备好进入黄金时代。
Regenerative Medicine: Tremendous Potential but Not Quite Ready for Prime-Time.
作者信息
Rodeo Scott A
机构信息
Hospital for Special Surgery, Sports Medicine Institute, New York, NY, USA.
出版信息
HSS J. 2025 Sep 4:15563316251366180. doi: 10.1177/15563316251366180.
Abstract
This guest editorial gives an overview of the field of regenerative medicine and the special issue.
摘要
这篇客座社论概述了再生医学领域以及本期特刊的内容。
相似文献
1
Regenerative Medicine: Tremendous Potential but Not Quite Ready for Prime-Time.再生医学：潜力巨大，但尚未完全准备好进入黄金时代。
HSS J. 2025 Sep 4:15563316251366180. doi: 10.1177/15563316251366180.
2
The Ethical Implications of Tissue Engineering for Regenerative Purposes: A Systematic Review.组织工程用于再生目的的伦理影响：系统评价。
Tissue Eng Part B Rev. 2023 Apr;29(2):167-187. doi: 10.1089/ten.TEB.2022.0033. Epub 2022 Oct 20.
3
Ethical and Regulatory Considerations Related to Regenerative Medicine.与再生医学相关的伦理和监管考量
HSS J. 2025 Aug 30:15563316251361511. doi: 10.1177/15563316251361511.
4
Clinical applications of dental stem cells in modern regenerative medicine: A systematic review with updates.现代再生医学中牙髓干细胞的临床应用：系统评价与更新。
Niger J Clin Pract. 2021 Apr;24(4):457-463. doi: 10.4103/njcp.njcp_498_20.
6
Advanced biomaterials for regenerative medicine and their possible therapeutic significance in treating COVID-19: a critical overview.用于再生医学的先进生物材料及其在治疗新冠肺炎中的潜在治疗意义：批判性综述
Int J Surg. 2024 Dec 1;110(12):7508-7527. doi: 10.1097/JS9.0000000000002110.
7
Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews.改善消费者安全有效用药的干预措施：系统评价概述
Cochrane Database Syst Rev. 2014 Apr 29;2014(4):CD007768. doi: 10.1002/14651858.CD007768.pub3.
8
iPSCs chondrogenic differentiation for personalized regenerative medicine: a literature review.iPSCs 软骨分化在个性化再生医学中的应用：文献综述。
Stem Cell Res Ther. 2024 Jun 26;15(1):185. doi: 10.1186/s13287-024-03794-1.
9
Menstrual blood and endometrial mesenchymal stem/stromal cells: A frontier in regenerative medicine and cancer therapy.月经血与子宫内膜间充质干/基质细胞：再生医学与癌症治疗的前沿领域。
Eur J Pharmacol. 2025 Aug 5;1000:177726. doi: 10.1016/j.ejphar.2025.177726. Epub 2025 May 9.
10
Musculoskeletal organoids: An emerging toolkit for establishing personalized models of musculoskeletal disorders and developing regenerative therapies.肌肉骨骼类器官：一种用于建立肌肉骨骼疾病个性化模型和开发再生疗法的新兴工具。
Acta Biomater. 2025 Jun 15;200:158-186. doi: 10.1016/j.actbio.2025.05.037. Epub 2025 May 15.
本文引用的文献
1
Priorities for a New FDA.美国食品药品监督管理局的新工作重点
JAMA. 2025 Aug 19;334(7):565-566. doi: 10.1001/jama.2025.10116.
2
Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson's disease.用于帕金森病的诱导多能干细胞衍生多巴胺能细胞的I/II期试验。
Nature. 2025 May;641(8064):971-977. doi: 10.1038/s41586-025-08700-0. Epub 2025 Apr 16.
3
Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR/Cas9 gene therapy for sickle cell disease.革命性突破：美国食品药品监督管理局（FDA）批准了CASGEVY，这是首个用于治疗镰状细胞病的CRISPR/Cas9基因疗法。
Ann Med Surg (Lond). 2024 May 15;86(8):4555-4559. doi: 10.1097/MS9.0000000000002146. eCollection 2024 Aug.
Zotero 插件